Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study

Cancer

Volumn 123, Issue 19, 2017, Pages 3754-3762

  Zeidan, Amer M ^a,b   Hu, Xin ^b   Long, Jessica B ^b   Wang, Rong ^b   Ma, Xiaomei ^b   Podoltsev, Nikolai A ^a   Huntington, Scott F ^a,b   Gore, Steven D ^a,b   Davidoff, Amy J ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

and End Results (SEER); azacitidine; chronic myelomonocytic leukemia (CMML); decitabine; effectiveness; Epidemiology; hypomethylating agents; Medicare; Surveillance; survival

Indexed keywords

AZACITIDINE; DECITABINE; ANTINEOPLASTIC ANTIMETABOLITE;

AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MORTALITY RISK; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; UNITED STATES; VERY ELDERLY; ANALOGS AND DERIVATIVES; CANCER REGISTRY; CASE CONTROL STUDY; KAPLAN MEIER METHOD; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MEDICARE; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CASE-CONTROL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MEDICARE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 85021445883     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30814     Document Type: Article

References (23)

1. Nazha A, Prebet T, Gore S, Zeidan AM. Chronic myelomonocytic leukemia: are we finally solving the identity crisis? Blood Rev. 2016;30:381-388.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
3. Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015;22:163-170.
4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
6. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
7. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987-1996.
8. Fletcher SA, Cronin AM, Zeidan AM, et al. Intensity of end-of-life care for patients with myelodysplastic syndromes: findings from a large national database. Cancer. 2016;122:1209-1215.
9. Zeidan AM, Wang R, Davidoff AJ, et al. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer. 2016;122:1598-1607.
10. Wang R, Zeidan AM, Yu JB, et al. Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study. Prostate. 2017;77:437-445.
11. Zandberg DP, Huang TY, Ke X, et al. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica. 2013;98:584-590.
12. Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175:829-840.
13. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20:307-316.
14. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-18.
15. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
16. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
17. Davidoff AJ, Zuckerman IH, Pandya N, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol. 2013;4:157-165.
18. Davidoff AJ, Gardner LD, Zuckerman IH, Hendrick F, Ke X, Edelman MJ. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care. 2014;52:500-510.
19. Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333.
20. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109:713-717.
21. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008;32:587-591.
22. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118:3824-3831.
23. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117:2690-2696.